Company Overview of GlycoGenesys Inc.
On December 30, 2009, GlycoGenesys, Inc. went out of business as per its Chapter 7 liquidation filing under bankruptcy. GlycoGenesys, Inc. engages in the research and development of carbohydrate-based products, as well as related technologies in the area of oncology. Its lead product candidate includes GCS-100, a phase II clinical trial product, which would be used for the treatment of solid tumors and bloodborne cancers. The company was founded in 1987. It was formerly known as IGG International, Inc. and changed its name to SafeScience, Inc. in 1998; and then to GlycoGenesys, Inc. in 2001. GlycoGenesys is headquartered in Boston, Massachusetts.
Park Square Building
31 St James Avenue 8th Floor
Boston, MA 02116
Founded in 1987
Key Executives for GlycoGenesys Inc.
GlycoGenesys Inc. does not have any Key Executives recorded.
GlycoGenesys Inc. Key Developments
Similar Private Companies By Industry
|GNI USA, Inc.||United States|
|MorepenMax Inc||United States|
|X-Ceptor Therapeutics, Inc.||United States|
|SciFluor Life Sciences, LLC||United States|
|MonoSol Rx, LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|NYC2012, Inc.||United States|
|Lawyers Committee for Civil Rights Under Law||United States|
|Rush University||United States|
|Citizens Budget Commission||United States|
Post a JobJobs
- Germany, PA | Life TechnologiesPosted: Nov 22
- New London, CT | Affinity Medical GroupPosted: Dec 11
- Billerica, MA | Mergis Group, A Division of SpherionPosted: Dec 10
- Spring House, PA | Leader of Pharmaceuticals, Medical Devices, and Consumer Goods CompanyPosted: Dec 06
Sponsored Financial Commentaries
To contact GlycoGenesys Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.